Seeking Alpha

Raptor Pharmaceutical (RPTP -6.5%) slips after it says that the FDA will need an extra three...

Raptor Pharmaceutical (RPTP -6.5%) slips after it says that the FDA will need an extra three months to review the company's Proscysbi drug candidate to treat nephropathic cystinosis, a genetic disease typically affecting young children and infants.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)